You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: Fluid Discovery Inc Topic: 400
Abstract The advance of biotechnology is dependent on approaches for rapidly iterating through genetically engineered enzymes and pathways. While computational and gene synthesis techniques have seen considerable innovation in the last few decades, screening variants for desired activities has lagged behind, with few notable advances. Indeed, microwell plates, a nearly 60-year-old technology, rema ...STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: Renova Therapeutics, Inc. Topic: NHLBI
ABSTRACT Type-1 Diabetes Mellitus (T1DM) affects 1.25 million patients in US with 40,000 new patients annually. Lifespan is shortened 11-13 years, due to kidney and heart disease. Tight glucose control reduces microvascular complications and adverse cardiovascular events. Insulin therapy is essential for such patients, but has shortcomings: a) only 1 in 3 patients achieve targeted glucose control ...STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
Development of novel, targeted small molecule inhibitors of DNA repair in high unmet need tumors-TNBCSBC: DNATWO, Inc. Topic: NCI
DNATWO, Inc. was founded out of Caltech to develop small molecule drugs targeting a new cancer target, DNA2, to treat triple-negative breast cancer (TNBC). We have spent decades unraveling the role of the DNA2 ATP-motor driven nuclease activity in relieving replication stress at the replication fork and carrying out repair at forks collapsed to double strand breaks (DSBs). Our scientific premise i ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: Olfa Thera, Inc. Topic: NIDA
Project Summary/AbstractThe opioid epidemic is a growing public health crisis with dramatic increase in overdose deaths caused by potent opioids like fentanyl. Currently, the standard treatment for opioid-induced respiratory depression is naloxone, a µ-opioid receptor antagonist. However, naloxone is less effective against potent synthetic opioids like fentanyl and induces withdrawal in chronic o ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: OASIS PHARMACEUTICALS, LLC Topic: NCI
Hepatocellular carcinoma (HCC) has become the second leading cause of cancer-related death in the world, with a 72% mortality rate in the US. The rise in incidence of HCC is due to a steady increase in the major risk factors of liver fibrosis, cirrhosis, and hepatitis B/C, with limited efficacy conferred by existing treatments at advanced stages of the disease. Systemic therapy with tyrosine kinas ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Development of negative allosteric modulators of the mu-opioid receptor for the management of opioid use disorderSBC: ELEVEN THERAPEUTICS CORP Topic: NIDA
Abstract There is a significant need for new treatments for opioid use disorder (OUD) to manage patients abusing heroin, fentanyl, oxycodone and related drugs. Buprenorphine and methadone are both effective medications for OUD but are agonists with potential for abuse and diversion, and with methadone the risk of respiratory depression and overdose death. Moreover, these compounds are not effectiv ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Self-Supervised Training in Geospatial Applications with a Robust Hierarchical Vision Transformer (STAR)SBC: UNIVERSITY TECHNICAL SERVICES, INC. Topic: OSD22A001
Satellite Imagery in Geospatial Intelligence (GEOINT), in conjunction with imagery intelligence (IMINT), geospatial information, and other means of gaining intelligence, has greatly improved the potential of the warfighter and decision makers enabling them to gain a more comprehensive perspective, an in-depth understanding, and a cross-functional awareness of the operational environment. The Artif ...STTR Phase I 2022 Department of DefenseNational Geospatial-Intelligence Agency
SBC: GENERAL NANOTHERAPEUTICS LLC Topic: NIAID
ABSTRACT Current pharmaceutical agents that are used for the treatment of immune-mediated inflammatory conditions including autoimmune diseases generally do not lead to remission and frequently carry toxic side effects. Here we propose a strategy that can harness the capacity of the immune system to induce immunoregulatory response that can suppress immune hyperactivity and chronic inflammation in ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: NIAID
PROJECT SUMMARY There is an urgent need for the development of new approaches to treat patients suffering from pulmonary injury from viral infections, as demonstrated by the severe impact of COVID-19, which is a global pandemic that, at the time of writing, is estimated have impacted approximately 50 million people in the United States, leading to morbidity, substantial hospital and intensive care ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: TENDEL THERAPIES INC Topic: NIAID
This project will establish proof-of-concept for CCR5 immunotoxins as HIV reservoir-depletion agents for use in cure strategies. HIV cure and remission strategies require elimination or reduction of the HIV reservoir. Approaches to reservoir reduction pursued by other groups include gene editing, i.e., direct removal of integrated provirus; latency reversal and an accompanying “kill” strategy; ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health